Twist Bioscience (TWST) Stock Price
Twist Bioscience Price
Over the last 9 years Twist Bioscience grew revenue by 84.5% annually, reaching 376.57 M USD. For Twist Bioscience, the net margin of -20.6% is up versus -115.3% a few years ago. The consensus 12-month price target for Twist Bioscience is 107.00 USD, about 31.3% below where the stock trades today. Of 16 analysts, 14 rate the stock a buy — an overall Buy consensus.
Twist Bioscience stock price
Twist Bioscience business model & stock analysis
Frequently asked questions about Twist Bioscience
The business model of Twist Bioscience Corp revolves around synthetic biology and DNA synthesis. Twist Bioscience is a leading company specializing in the production and commercialization of synthetic DNA constructs. The company offers comprehensive solutions that enable researchers and industries to leverage the power of DNA synthesis for various applications, including precision medicine, agricultural biotechnology, and industrial chemicals. Twist Bioscience employs a high-throughput silicon-based DNA synthesis platform, empowering scientists to rapidly and cost-effectively create customized genes, antibodies, and other DNA-based products. With its innovative technology and extensive product portfolio, Twist Bioscience Corp aims to drive discovery, accelerate development, and address real-world challenges through advanced synthetic biology solutions.
Twist Bioscience Corp is primarily active in the biotechnology and life sciences industries.
The main competitors of Twist Bioscience Corp in the market are GenScript Biotech Corporation, Integrated DNA Technologies, and Eurofins Genomics.
Twist Bioscience Corp, a leading company in synthetic biology, was founded in 2013. It aims to revolutionize the way DNA is being synthesized by providing high-quality, custom DNA at scale. The company's innovative silicon platform enables the efficient production of DNA, RNA, and proteins. With a vast portfolio of products and services, Twist Bioscience Corp caters to various industries such as healthcare, pharmaceuticals, agriculture, and industrial chemicals. By leveraging its proprietary technology, the company has secured partnerships with renowned organizations worldwide. Today, Twist Bioscience Corp continues to push the boundaries of synthetic biology, promoting advancements in fields ranging from drug discovery to data storage.
Twist Bioscience Corp has achieved several significant milestones. The company successfully launched the Twist Bioscience Tool Suite, a powerful set of DNA writing tools enabling researchers to generate synthetic DNA at scale. Additionally, Twist Bioscience Corp collaborated with Microsoft and researchers to store and retrieve digital data using DNA. The company also introduced the Twist Bioscience NGS Target Enrichment Solution, revolutionizing next-generation sequencing applications. Furthermore, Twist Bioscience Corp expanded its product portfolio by launching the Twist Human Core Exome Kit, facilitating the comprehensive analysis of genetic variations. These milestones showcase the company's commitment to innovation and its role in advancing genetic research and development.
Twist Bioscience Corp is primarily present in the United States, with headquarters located in South San Francisco, California. The company also has a strong presence in Europe, specifically in the United Kingdom and Germany. Additionally, Twist Bioscience Corp has expanded its reach into the Asia-Pacific region, with operations in Singapore and China. With a focus on synthetic biology and DNA synthesis, Twist Bioscience Corp is at the forefront of genetic engineering advancements. The company's innovative solutions and partnerships have allowed it to establish a global presence in the biotechnology industry.
Twist Bioscience Corp represents innovative values and a strong corporate philosophy. With a focus on synthetic biology, the company aims to accelerate breakthroughs in areas like healthcare, sustainability, and data storage. Twist Bioscience believes in the power of DNA synthesis technology to enable a wide range of applications that can transform multiple industries. By providing high-quality, custom DNA synthesis solutions, the company strives to empower researchers, scientists, and industry partners to create novel solutions and drive scientific advancements. Leveraging their expertise in DNA synthesis and bioinformatics, Twist Bioscience Corp is committed to fostering a more sustainable, healthier, and data-driven future.
Analysts currently set an average price target of 104.67 USD for the Twist Bioscience stock (median: 107.00 USD), implying -32.8 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Twist Bioscience stock: 14 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Twist Bioscience to generate revenue of 456.38 M USD and earnings per share of -2.11 USD.
Converted at the current exchange rate, the Twist Bioscience share trades at 138.99 EUR (155.65 USD).
The Twist Bioscience share (TWST) is listed on 4 stock exchanges, including: NASDAQ (TWST), Frankfurt (0ME.F), München (0ME.MU), Düsseldorf (0ME.DU).
Twist Bioscience Corp was founded in 2013 in San Francisco and specializes in the production of synthetic DNA strands used in research and biotechnology. Their business model is based on their proprietary synthesis technology, which allows them to produce large quantities of high-quality, customized DNA quickly and cost-effectively. The company offers its products and services in four main areas: 1. DNA synthesis: Twist Bioscience offers a variety of DNA synthesis products used by researchers, companies, and government agencies. They produce synthetic DNA strands in various formats and sizes, including DNA primers, oligonucleotides, gene fragments, and complete genes. 2. Data and information analysis: To effectively work with Twist Bioscience, it is important for customers to analyze and understand the data from their DNA samples. Therefore, the company has developed a platform for data and information analysis that allows customers to process their genetic data quickly and easily. 3. Bio-products: Twist Bioscience has developed a variety of bio-products based on their DNA technology. These products include antibodies, RNA probes, protein A colloids, and other biological reagents. 4. DNA storage: In addition to their DNA production activity, Twist Bioscience has also developed a technology for storing data on synthetic DNA. This method of data storage is designed to enable long-term, secure, and cost-effective storage of large amounts of data. Twist Bioscience has customers worldwide in fields such as biotechnology, pharmaceuticals, diagnostics, agriculture, and the research community overall. It also works closely with government agencies to create solutions for bio-scientific critical applications and meet the growing demands of the market. Through its DNA synthesis products and information analysis, bio-products, and innovative DNA storage technology, Twist Bioscience remains at the forefront of genomics and biotechnology. The company has received several patents and awards, including the "Best Workplace" award from the San Francisco Business Times and the Silicon Valley Business Journal in 2018. Its expanding presence in Asian markets and successful expansion even during the COVID-19 pandemic period are among its key success factors.
The expected revenue of Twist Bioscience is 456.38 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Twist Bioscience is -129.01 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Twist Bioscience is currently -73.70. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Twist Bioscience stock.
The price-to-sales ratio (P/S) of Twist Bioscience is currently 20.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Twist Bioscience stock.
The Eulerpool Quality Score for Twist Bioscience is 3/10.
The ISIN of Twist Bioscience is US90184D1000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Twist Bioscience is A2N7L2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Twist Bioscience is TWST. The ticker symbol is used to trade Twist Bioscience shares on the stock exchange.
Twist Bioscience stock
Twist Bioscience Peer Group
Twist Bioscience Ticker
Twist Bioscience FIGI
All fundamentals and in-depth analysis of Twist Bioscience
Our stock analysis for Twist Bioscience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Twist Bioscience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.